Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers.
about
A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian CancerCost of contralateral prophylactic mastectomyA simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers.Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis.Contralateral risk-reducing mastectomy: review of risk factors and risk-reducing strategies.Factors associated with altered long-term well-being after prophylactic salpingo-oophorectomy among women at increased hereditary risk for breast and ovarian cancer.Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysisOnline tool to guide decisions for BRCA1/2 mutation carriers.A preliminary investigation of genetic counselors' information needs when receiving a variant of uncertain significance result: a mixed methods studyBreast Cancer Survivors' Knowledge of Hereditary Breast and Ovarian Cancer following Genetic Counseling: An Exploration of General and Survivor-Specific Knowledge Items.Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriersEconomic evaluation of targeted cancer interventions: critical review and recommendations.Contralateral Prophylactic Mastectomy Consensus Statement from the American Society of Breast Surgeons: Additional Considerations and a Framework for Shared Decision Making.Decision making for breast cancer prevention among women at elevated riskBreast cancer screening: review of benefits and harms, and recommendations for developing and low-income countries.The peculiar economics of life-extending therapies: a review of costing methods in health economic evaluations in oncology.Contralateral Prophylactic Mastectomy with Immediate Breast Reconstruction Increases Healthcare Utilization and Cost.Surgical Decision Making in the BRCA-Positive Population: Institutional Experience and Comparison with Recent Literature.Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation.The financial cost of preventive and curative programs for breast cancer: a case study of women in Shiraz-Iran.Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcome.Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.Comparative effectiveness of incorporating a hypothetical DCIS prognostic marker into breast cancer screening.From the laboratory to the clinic: sharing BRCA VUS reclassification tools with practicing genetics professionals.Cost-effectiveness and comparative effectiveness of cancer risk management strategies in BRCA1/2 mutation carriers: a systematic review.Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer.Population-Based BRCA1/2 Testing in Ashkenazi Jews: Ready for Prime Time.
P2860
Q33606561-09C51A18-4F41-410D-9D2B-F37B0A387535Q34017128-0D604606-0B08-4EFD-AAB2-60D25FF53800Q34097351-CF000CB2-9E3F-488B-8651-3993EC823B4DQ34663394-837C3159-2DF3-4651-968D-67966D75DE5DQ35066801-A11B0395-202B-45AD-8D02-42B278B6BF1CQ35584792-46244093-AF71-4933-9BE6-5C6693E08445Q35633057-5F9EF995-2442-4E8F-B6B3-A681DAB21D38Q35808372-EDFF2BD0-92C7-4FBC-B213-6C63160781E6Q35832845-AA6AE4F7-2E9D-43E4-A5B3-BFEEF2E18B39Q36567487-E9823581-AC34-4E73-8617-09CE6FF61059Q36652732-736CB2B6-0533-47B3-9526-2B2D773D9540Q37173971-8FA769C4-53D8-4319-BD37-0FAFD32907D5Q37208201-E2B51F24-7FFE-42E8-A5A5-724714050F41Q37720955-03F15B84-DE75-489A-AF3A-61E62ADE2FC7Q38082665-8E237A0A-52BF-4EA0-AEDB-A6ECE4997F29Q38610648-4963F0A9-31D3-4CCC-923D-19972AA827A2Q38647477-8BDBCF08-E930-4DD7-9117-C25A1362966DQ38676694-DEF1E333-D2BD-482D-8003-8FF4C8A9D786Q38851169-75376F43-5189-44D5-95B5-B4C202BFE64EQ39715471-EAEC5A6D-57C5-41FB-A835-B6C47BF0E2C5Q44941961-748B731B-AF95-4C94-9B94-7EB54B3AF462Q47246829-819C8967-3077-4BF1-A0DF-AB58216A209EQ47304201-0967486E-0B54-43A1-AD64-9BE340281509Q48328498-16804F0A-06F6-4F5D-9536-AAF03E871960Q50091589-C0402C64-A61D-4052-8CF1-952DC0D0A512Q51346860-C127E1CA-B92E-4F39-A41F-60DA99C317A8Q53083669-4AAB3871-DF0E-4E5C-B323-CAE71A7A44F3
P2860
Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Comparative effectiveness of s ...... /2-affected mutation carriers.
@ast
Comparative effectiveness of s ...... /2-affected mutation carriers.
@en
type
label
Comparative effectiveness of s ...... /2-affected mutation carriers.
@ast
Comparative effectiveness of s ...... /2-affected mutation carriers.
@en
prefLabel
Comparative effectiveness of s ...... /2-affected mutation carriers.
@ast
Comparative effectiveness of s ...... /2-affected mutation carriers.
@en
P2093
P2860
P1476
Comparative effectiveness of s ...... /2-affected mutation carriers.
@en
P2093
Alfred I Neugut
Daniel F Heitjan
Ellen Warner
Judith S Jacobson
Maxine Ashby-Thompson
Priya R Patel
Victor R Grann
P2860
P2888
P304
P356
10.1007/S10549-010-1043-4
P407
P577
2010-07-20T00:00:00Z